Cell therapy · Kills target cells, directed at autologous leukemic B-cells · developed by IOVANCE BIOTHERAPEUTICS
IOV-2001 is an autologous cell therapy manufactured from peripheral blood lymphocytes harvested from chronic lymphocytic leukemia patients previously treated with ibrutinib. The product, enriched for effector memory T-cells, generates enhanced cytotoxic T-cell responses against autologous leukemic B-cells in patients who have relapsed during ibrutinib treatment. It is studied in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04155710 | Phase 1 | Chronic Lymphocytic Leukemia | Completed | IOVA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Updated Oct 3, 2026. Something wrong or missing? Report it on the IOVA page.
See IOVA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IOVA catalysts and pipeline →